PDS Biotechnology Soars 17.83% on Positive Cancer Trial Data

On May 23, 2025, PDS Biotechnology's stock surged by 17.83% in pre-market trading, reflecting significant investor optimism and market confidence in the company's recent developments.

PDS Biotechnology has announced positive extended follow-up data for the VERSATILE-002 trial, which evaluated Versamune® HPV in head and neck cancer patients. The trial demonstrated a median overall survival of 39.3 months for patients with a Combined Positive Score (CPS) of 20, highlighting the potential efficacy of the treatment.

Additionally, the company will present several abstracts during the Head and Neck Cancer Poster Session, scheduled from May 30 to June 3, 2025. These presentations will include updates on the ongoing VERSATILE-003 trial and other studies involving Versamune® HPV, further underscoring the company's commitment to advancing cancer treatments.

PDS Biotechnology's encouraging survival data for Versamune® HPV combined with pembrolizumab in head and neck cancer trials has also contributed to the positive market sentiment. This data suggests that the combination therapy may offer promising outcomes for patients, potentially driving further investment in the company's research and development efforts.